Differently from these studies, therefore, the aim of our analysis was not to verify if patients with possible contemporary presence of LRRK2 mutations and parkin mutations could present an earlier age-at-onset or a faster progression of disease, but, more precisely, if presence of this combination could have influenced the penetrance of PD in these patients. This evidence concerns the gene LRRK2 and Parkinson disease.